Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924727 · ClinicalTrials.gov registry record · Phase 3
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,669
- Enrollment target
NCT02924727 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 5,669 participants.
The verdict
NCT02924727, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,669 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
Interventions
- DRUG Ramipril
- DRUG Valsartan
- DRUG Placebo of LCZ696
- DRUG LCZ696 (sacubitril/valsartan)
- DRUG Placebo of ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,669 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924727
The ClinicalTrials.gov registry entry for NCT02924727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,669 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ramipril is the first listed.
NCT02924727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02924727 about?
NCT02924727 is a clinical study titled "Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI". The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
What is the current status of trial NCT02924727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,669 participants. The study started on 2016-12-09. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT02924727?
The interventions under investigation include: Ramipril (DRUG), Valsartan (DRUG), Placebo of LCZ696 (DRUG), LCZ696 (sacubitril/valsartan) (DRUG), Placebo of ramipril (DRUG).
Who is sponsoring clinical trial NCT02924727?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.